Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Erucin is a naturally occurring isothiocyanate, specifically 4-methylthiobutyl isothiocyanate, found predominantly in cruciferous vegetables such as arugula (Eruca sativa) and related Brassicaceae plants. It is formed by the enzymatic hydrolysis of its precursor, glucoerucin, a glucosinolate. Erucin possesses potent antioxidative, anti-inflammatory, neuroprotective, anticancer chemotherapeutic, and chemopreventive properties. Mechanistically, it induces cellular phase II detoxification enzymes (e.g., glutathione transferase, quinone reductase), inhibits proliferation and induces apoptosis in cancer cells (notably via the p53 and p21 pathways and PARP-1 cleavage), and suppresses inflammatory mediators such as IL-6, IL-1β, TNF-α, iNOS, and COX-2. It has shown activity inhibiting telomerase and reducing tumor growth in various cancer models, as well as neuroprotective effects in cellular models of Parkinson’s disease through Nrf2 activation and increased glutathione levels. It may involve direct or indirect modulation of targets such as the nuclear factor erythroid 2-related factor 2 (Nrf2), nuclear factor NF-κB p105 subunit (NF-κB), and transient receptor potential channels[1][2][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on erucin.